Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
|Videos|November 22, 2022
PharmExec Interviews at Pharma Lalarukh Haris Shaikh 2022
Advertisement
In this video, “Lala” Haris Shaikh, PhD, Executive Vice President, Life Sciences & Biotech, Palantir Technologies discusses the digital transformation with pharma data, how that can be done, data insights for pharma leaders as well as data interoperability and integration issues.
Advertisement
Related to this article
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Launches Rare Disease Framework Initiative
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO-XTEN Dual Masked T-Cell Engagers
5